Science 37: public trading on Nasdaq
Trial technology company Science 37 has announced it is now a publicly traded company on Nasdaq, under the ticker symbol SNCE. The news comes along with the close of its business combination with LifeSci Acquisition II Corp.
David Coman, Science 37 CEO, said, “The additional capital from this transaction will help us deliver on our vision to be the category-defining operating system that powers every clinical trial as the industry shifts to more agile trial designs.”